Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient
- 85 Downloads
A 48-year-old, 92-kg male presented at the Emergency Department after 5 days of fever, cough, and fatigue. Underlying diseases included scleromyxedema, a rare connective tissue disease of unknown etiology , monoclonal gammopathy of undetermined significance (MGUS), and methylenetetrahydrofolate reductase (MTHFR) deficiency-related hyperhomocysteinemia. Because of these diseases, he had had repeated hospital accesses in the previous months, both in hematological and in rheumatological wards. At admission, chest CT scan revealed right-sided pulmonary thickening suggestive of pneumonia. The patient’s clinical conditions rapidly worsened [C-reactive protein (CRP) of 142 mg/L (reference range 0–5 mg/L) and pro-calcitonin (PCT) of 7.06 ng/mL (reference range < 0.10 ng/mL)]. He experienced septic shock, with multiple organ failure and seizure, and was transferred to the intensive care unit (ICU). Estimated creatinine clearance [eCrCL] was 10.1 mL/min/1.73 m2, and continuous venovenous...
Compliance with ethical standards
Conflict of interest
M. B. has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, AstraZeneca, Bayer, Basilea, Gilead, Menarini, MSD, Pfizer, The Medicines Company, Tetraphase and Vifor. F. P. has received speaker honoraria from Accelerate Diagnostics, Angelini, Astra Zeneca, Basilea Pharmaceutica, Forest, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, Thermo Fisher and attended advisory boards for Basilea Pharmaceutics, Gileads, MSD and Pfizer. All other authors have none to declare.
- 2.Torres A, Mouton JW, Pea F (2016) Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital- and community-acquired pneumonia in different patient populations. Clin Pharmacokinet 55(12):1507–1520. https://doi.org/10.1007/s40262-016-0418-z CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW (2012) Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34(4):467–476. https://doi.org/10.1097/FTD.0b013e31825c4ba6 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Schmitt-Hoffmann A, Nyman L, Roos B, Schleimer M, Sauer J, Nashed N, Brown T, Man A, Weidekamm E (2004) Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 48(7):2576–2580. https://doi.org/10.1128/aac.48.7.2576-2580.2004 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Schmitt-Hoffmann A, Roos B, Schleimer M, Sauer J, Man A, Nashed N, Brown T, Perez A, Weidekamm E, Kovacs P (2004) Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 48(7):2570–2575. https://doi.org/10.1128/aac.48.7.2570-2575.2004 CrossRefPubMedPubMedCentralGoogle Scholar